Posts Tagged ‘nivolumab’

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Posted by • November 9th, 2016

A 62-year-old man with a history of smoking and excess alcohol use presented with a two-month history of hoarseness and dysphagia and was diagnosed with laryngeal squamous cell carcinoma. Five months after completing concurrent cisplatin and radiation therapy, he returns to his oncologist with lung metastases. He asks about additional therapeutic options for his cancer… Read More…

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

Posted by • November 2nd, 2016

Oncologists and patients with cancer eagerly await new therapies that efficiently target cancer and avoid damage to normal tissues. In 2015, a randomised controlled trial investigated the role of two immune checkpoint inhibitors: ipilimumab — an anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody — and nivolumab — an anti-programmed death-1 (PD-1) antibody. Patients with untreated metastatic… Read More…

Nivolumab in Renal-Cell Carcinoma

Posted by • November 6th, 2015

In a randomized trial involving patients with advanced previously treated renal-cell carcinoma, nivolumab produced higher response rates than everolimus (25% vs. 5%) and median overall survival was longer (by 5.4 months), to more than 2 years. A new Original Article summarizes. Each year, an estimated 338,000 new cases of renal-cell carcinoma are diagnosed worldwide, and approximately 30%… Read More…

Advanced Renal Cancer: What is a Breakthrough Worth?

Posted by • November 4th, 2015

When I tell people that I am a resident in urology, they often ask me why I chose this field. There are many reasons, but one of my primary motivations was to treat renal cancer, a disease that has affected several people close to me. With early detection, surgery can be curative. Unfortunately, a third… Read More…

PD-1 Blockade with Nivolumab

Posted by • January 23rd, 2015

Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. An ongoing phase 1 study tests the hypothesis that nivolumab, a PD-1-blocking antibody, can inhibit tumor immune evasion in patients with relapsed or refractory Hodgkin’s lymphoma. Clinical Pearls – How do tumors exploit the PD-1 [programmed death 1] pathway? The… Read More…